Nifty
Sensex
:
:
11419.25
38337.01
-177.65 (-1.53%)
-560.45 (-1.44%)

Pharmaceuticals & Drugs

Rating :
69/99

BSE: 539523 | NSE: ALKEM

1798.45
40.40 (2.30%)
19-Jul-2019 | 3:53PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  1757.35
  •  1809.10
  •  1735.30
  •  1758.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  25683
  •  461.90
  •  2268.00
  •  1661.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 21,495.99
  • 27.59
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 21,916.77
  • 0.72%
  • 3.86

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 66.03%
  • 2.71%
  • 22.28%
  • FII
  • DII
  • Others
  • 0.12%
  • 5.93%
  • 2.93%

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.40
  • 15.49
  • 9.25

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 21.23
  • 20.19
  • 3.80

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.47
  • 7.71
  • -5.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 31.29

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 4.81

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 20.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
1,854.20
1,513.23
22.53%
1,925.03
1,741.19
10.56%
1,918.92
1,858.98
3.22%
1,669.46
1,312.54
27.19%
Expenses
1,619.19
1,399.48
15.70%
1,613.25
1,380.66
16.85%
1,554.75
1,404.48
10.70%
1,455.23
1,218.17
19.46%
EBITDA
235.01
113.75
106.60%
311.78
360.53
-13.52%
364.17
454.50
-19.87%
214.23
94.37
127.01%
EBIDTM
12.67%
7.52%
16.20%
20.71%
18.98%
24.45%
12.83%
7.19%
Other Income
27.66
17.87
54.78%
9.35
23.86
-60.81%
24.02
29.97
-19.85%
16.25
29.49
-44.90%
Interest
6.59
10.44
-36.88%
15.38
14.48
6.22%
16.40
17.85
-8.12%
16.26
12.56
29.46%
Depreciation
57.27
40.33
42.00%
47.69
37.50
27.17%
45.77
34.57
32.40%
42.45
30.63
38.59%
PBT
198.81
80.85
145.90%
258.06
332.41
-22.37%
326.02
432.05
-24.54%
171.77
80.67
112.93%
Tax
28.31
14.52
94.97%
52.61
151.54
-65.28%
65.60
104.61
-37.29%
34.50
16.89
104.26%
PAT
170.50
66.33
157.05%
205.45
180.87
13.59%
260.42
327.44
-20.47%
137.27
63.78
115.22%
PATM
9.20%
4.38%
10.67%
10.39%
13.57%
17.61%
8.22%
4.86%
EPS
14.00
5.61
149.55%
16.94
14.36
17.97%
21.29
26.82
-20.62%
11.39
5.99
90.15%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
7,367.61
6,421.85
5,687.53
4,924.84
3,743.35
3,126.00
2,495.23
2,015.64
1,690.79
Net Sales Growth
14.65%
12.91%
15.49%
31.56%
19.75%
25.28%
23.79%
19.21%
 
Cost Of Goods Sold
3,028.63
2,116.59
1,807.71
1,630.87
1,453.41
1,168.05
866.74
645.76
597.04
Gross Profit
4,338.98
4,305.26
3,879.82
3,293.97
2,289.94
1,957.95
1,628.49
1,369.88
1,093.75
GP Margin
58.89%
67.04%
68.22%
66.88%
61.17%
62.63%
65.26%
67.96%
64.69%
Total Expenditure
6,242.42
5,393.46
4,688.58
4,071.59
3,321.52
2,716.05
2,132.78
1,640.43
1,404.20
Power & Fuel Cost
-
112.64
86.34
66.33
53.31
60.33
53.17
50.68
37.78
% Of Sales
-
1.75%
1.52%
1.35%
1.42%
1.93%
2.13%
2.51%
2.23%
Employee Cost
-
1,191.64
1,003.85
861.08
645.87
531.56
412.29
303.45
267.09
% Of Sales
-
18.56%
17.65%
17.48%
17.25%
17.00%
16.52%
15.05%
15.80%
Manufacturing Exp.
-
708.72
692.26
550.16
367.58
305.99
264.84
234.61
195.99
% Of Sales
-
11.04%
12.17%
11.17%
9.82%
9.79%
10.61%
11.64%
11.59%
General & Admin Exp.
-
413.80
377.69
331.27
238.45
184.73
180.17
139.46
106.32
% Of Sales
-
6.44%
6.64%
6.73%
6.37%
5.91%
7.22%
6.92%
6.29%
Selling & Distn. Exp.
-
685.97
596.44
503.69
434.56
367.31
295.39
226.31
167.01
% Of Sales
-
10.68%
10.49%
10.23%
11.61%
11.75%
11.84%
11.23%
9.88%
Miscellaneous Exp.
-
164.10
124.29
128.19
128.34
98.08
60.18
40.16
32.97
% Of Sales
-
2.56%
2.19%
2.60%
3.43%
3.14%
2.41%
1.99%
1.95%
EBITDA
1,125.19
1,028.39
998.95
853.25
421.83
409.95
362.45
375.21
286.59
EBITDA Margin
15.27%
16.01%
17.56%
17.33%
11.27%
13.11%
14.53%
18.61%
16.95%
Other Income
77.28
95.95
112.01
239.71
181.04
165.35
167.17
145.28
113.42
Interest
54.63
55.33
45.16
71.24
81.11
93.08
88.23
58.10
41.23
Depreciation
193.18
143.03
101.17
93.31
70.94
52.26
39.79
29.03
27.43
PBT
954.66
925.98
964.63
928.41
450.82
429.96
401.60
433.36
331.35
Tax
181.02
287.56
59.96
176.18
59.23
-5.36
17.97
27.52
35.57
Tax Rate
18.96%
31.05%
6.22%
18.98%
13.14%
-1.25%
4.47%
6.35%
10.73%
PAT
773.64
630.94
892.03
741.59
391.59
435.32
383.82
406.54
295.59
PAT before Minority Interest
760.51
638.42
904.67
752.23
391.59
435.32
383.63
405.84
295.78
Minority Interest
-13.13
-7.48
-12.64
-10.64
0.00
0.00
0.19
0.70
-0.19
PAT Margin
10.50%
9.82%
15.68%
15.06%
10.46%
13.93%
15.38%
20.17%
17.48%
PAT Growth
21.18%
-29.27%
20.29%
89.38%
-10.05%
13.42%
-5.59%
37.54%
 
Unadjusted EPS
63.62
52.77
74.61
62.02
32.75
364.09
321.01
339.43
247.38

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
4,863.77
4,467.64
3,691.96
3,002.63
2,584.97
2,177.31
1,820.05
1,433.69
Share Capital
23.91
23.91
23.91
23.91
11.96
11.96
11.96
11.96
Total Reserves
4,838.87
4,443.34
3,668.03
2,978.72
2,573.01
2,165.35
1,808.09
1,421.73
Non-Current Liabilities
-358.61
-400.78
-306.15
197.02
323.92
361.67
524.89
434.40
Secured Loans
122.12
175.01
112.49
33.43
232.25
255.57
308.97
246.26
Unsecured Loans
8.61
6.55
10.97
0.00
0.00
0.02
0.00
0.00
Long Term Provisions
150.27
102.17
82.96
66.58
42.29
44.30
179.99
162.14
Current Liabilities
2,383.31
1,689.69
1,537.60
2,005.98
1,402.58
1,731.80
1,120.59
981.86
Trade Payables
960.71
741.37
580.48
465.93
305.73
287.59
276.03
167.69
Other Current Liabilities
520.04
339.25
366.01
327.06
201.28
187.74
111.47
87.39
Short Term Borrowings
761.27
472.37
464.17
1,128.57
845.22
1,210.17
670.31
663.10
Short Term Provisions
141.29
136.70
126.94
84.42
50.35
46.30
62.78
63.68
Total Liabilities
7,010.02
5,871.78
5,018.43
5,291.28
4,311.47
4,270.78
3,465.72
2,851.77
Net Block
2,283.60
1,797.04
1,449.54
1,374.34
1,170.01
1,072.12
919.17
692.73
Gross Block
2,603.78
1,977.20
1,538.64
1,744.89
1,170.01
1,072.12
919.17
692.73
Accumulated Depreciation
320.18
180.16
89.10
370.55
0.00
0.00
0.00
0.00
Non Current Assets
3,094.83
2,954.64
2,249.73
2,953.23
2,709.33
2,114.56
2,153.43
1,313.22
Capital Work in Progress
380.97
299.26
172.42
110.69
0.00
0.00
0.00
0.00
Non Current Investment
196.47
259.44
234.39
419.73
338.24
410.33
298.91
6.10
Long Term Loans & Adv.
141.37
193.07
142.35
542.17
418.40
339.39
258.82
153.98
Other Non Current Assets
92.42
405.83
251.03
506.30
782.68
292.72
676.53
460.41
Current Assets
3,915.19
2,917.14
2,768.70
2,338.05
1,602.14
2,156.22
1,312.29
1,538.55
Current Investments
247.80
293.56
274.18
61.05
249.77
67.31
23.78
47.70
Inventories
1,442.19
1,206.00
909.37
784.23
620.33
553.96
384.92
250.87
Sundry Debtors
1,080.50
713.64
567.51
527.08
366.93
318.21
246.61
171.02
Cash & Bank
576.78
399.26
780.90
790.76
206.29
995.45
513.81
989.82
Other Current Assets
567.92
133.33
95.44
60.08
158.82
221.29
143.17
79.14
Short Term Loans & Adv.
390.62
171.35
141.30
114.85
110.04
115.29
80.24
40.32
Net Current Assets
1,531.88
1,227.45
1,231.10
332.07
199.56
424.42
191.70
0.00
Total Assets
7,010.02
5,871.78
5,018.43
5,291.28
4,311.47
4,270.78
3,465.72
2,851.77

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
276.18
471.14
725.83
328.14
290.01
78.05
159.05
147.93
PBT
925.98
964.63
928.41
514.16
429.96
401.60
433.36
331.35
Adjustment
116.85
33.02
-14.42
15.89
7.48
-30.64
-32.93
-17.61
Changes in Working Capital
-563.48
-262.55
10.05
-96.27
-36.37
-182.68
-144.78
-99.22
Cash after chg. in Working capital
479.35
735.10
924.04
433.78
401.07
188.28
255.65
214.52
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-203.17
-263.96
-198.21
-105.64
-111.06
-110.23
-96.60
-66.59
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-367.37
-285.93
202.27
-237.00
350.44
-403.52
-247.50
-822.79
Net Fixed Assets
-531.27
-390.07
160.79
-111.90
-103.11
-213.73
-206.97
Net Investments
-26.86
-359.97
-87.11
-129.77
-361.40
-207.20
-318.96
Others
190.76
464.11
128.59
4.67
814.95
17.41
278.43
Cash from Financing Activity
84.56
-137.88
-927.27
-51.79
-599.94
355.64
-11.07
778.87
Net Cash Inflow / Outflow
-6.63
47.33
0.83
39.35
40.51
30.17
-99.52
104.01
Opening Cash & Equivalents
166.63
127.03
123.75
100.82
57.31
26.35
123.96
19.98
Closing Cash & Equivalent
166.71
166.63
127.05
139.60
100.82
57.31
26.35
123.96

Financial Ratios

Standalone /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
406.76
373.67
308.82
251.16
216.13
182.05
152.18
0.00
ROA
9.91%
16.61%
14.59%
8.16%
10.14%
9.92%
12.85%
10.37%
ROE
13.69%
22.18%
22.47%
14.02%
18.28%
19.19%
24.95%
20.63%
ROCE
17.86%
21.31%
23.09%
13.26%
14.06%
14.96%
19.02%
15.90%
Fixed Asset Turnover
2.81
3.33
3.07
2.65
2.89
2.59
2.57
2.49
Receivable days
50.91
39.95
39.57
42.27
38.62
40.02
36.80
36.14
Inventory Days
75.15
65.96
61.23
66.41
66.19
66.53
56.02
53.01
Payable days
60.92
52.36
49.96
45.83
42.61
49.36
50.29
47.05
Cash Conversion Cycle
65.15
53.55
50.84
62.85
62.19
57.20
42.53
42.10
Total Debt/Equity
0.21
0.15
0.18
0.43
0.44
0.71
0.55
0.00
Interest Cover
17.74
22.36
14.03
6.56
5.62
5.55
8.46
9.04

News Update:


  • Alkem Laboratories gets nod for commencing manufacturing unit in South Sikkim
    31st May 2019, 14:51 PM

    The company will close two units situated at Nani Daman and another unit situated at East Sikkim

    Read More
  • Alkem Laboratories reports around 3-fold jump in Q4 consolidated net profit
    30th May 2019, 14:48 PM

    The company has reported a standalone net profit of Rs 190.82 crore for the quarter ended March 31, 2019

    Read More
  • USFDA conducts inspection at Alkem Laboratories’ Baddi facility
    18th May 2019, 10:17 AM

    The company has received a Form 483 with four observations

    Read More
  • Alkem Laboratories receives classification letter from USFDA for its St. Louis facility
    15th May 2019, 09:12 AM

    USFDA had conducted Inspection at the company’s manufacturing facility located at St. Louis, USA

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.